Abstract. The aim of the study was 1) to estimate permeability of 5-aminosalicylic acid (5-ASA), 2) to categorize 5-ASA according to BCS (Biopharmaceutics Classification System), and 3) to contribute to determination of 5-ASA transintestinal transport and biotransformation mechanisms.
Introduction
revealed that the fundamental parameters controlling the rate and extent of oral drug absorption are the permeability of the drug through the gastrointestinal membrane and the solubility of the drug and devised Biopharmaceutics Classification System (BCS) that categorized drugs into four classes according to their solubility and permeability. Drug classes are defined as: Class 1: High solubility-high permeability drugs; Class 2: Low solubility-high permeability drugs; Class 3: High solubility-low permeability drugs; Class 4: Low solubility-low permeability drugs. The objective of the BCS is to predict in vivo pharmacokinetic performance of drug products from measurements of permeability and solubility. The BCS has provided a simple and facile scientific framework for drug development and in connection with dissolution may help decisions to obtain regulatory waivers for bioequivalence studies for oral drug formulations.
The models commonly used to determine drug permeability are, among others, in vitro model of the Caco-2 cell monolayer and the in situ model of rat intestinal perfusion (Kim et al. 2006) . No study categorizing 5-aminosalicylic acid (5-ASA; mesalazine), drug commonly prescribed in the treatment of inflammatory bowel diseases (Prakash and Markham 1999; Bergman and Parkes 2006) , into the BCS has been published so far. Oral 5-ASA preparations are generally formulated to release the drug in the terminal ileum and colon, where it is thought to exert its effects via topical actions (De Vos et al. 1992; Clemett and Markham 2000) . The absorbed portion of 5-ASA is almost completely acetylated in the gut wall and in the liver to its major metabolite N-acetyl-5-aminosalicylic acid (N-ac-5-ASA) (Zhou et al. 1999; Hu and Peppercorn 2008) . N-ac-5-ASA does not have an anti-inflammatory effect.
The in vitro experiments with transport of 5-ASA across Caco-2 monolayers have so far provided contradictory results. In the study of Zhou et al. (1999) some evidence was provided for carrier-mediated transepithelial transport at low concentrations of 5-ASA (65.4 µmol/l), which was saturable at higher levels (≥ 654 µmol/l). In the study of Liang et al. (2000) , 5-ASA (100 µmol/l) was not a substrate of efflux pumps. And also Xin et al. (2006) concluded in their study that the intestinal secretion of 5-ASA observed in vivo is unlikely to be mediated by the efflux transporters P-glycoprotein (P-gp) or multidrug resistance-associated protein 2 (MRP2). The involvement of organic anion transporting polypeptide (OATP) family in the transport mechanism of 5-ASA was suggested by König et al. (2011) .
The initial experiments utilized an in situ single-pass rat intestine perfusion method i) to study 5-ASA transport processes in the intestine and ii) to clarify whether metabolic conversion of 5-ASA to its metabolite (N-ac-5-ASA) occurs in the intestinal wall. The aim of Caco-2 experiments was 1) to estimate the permeability of 5-ASA, 2) to categorize 5-ASA into one of the BCS classes, and 3) to contribute to the determination of 5-ASA transintestinal transport mechanisms.
Materials and Methods

Rat intestine in situ single-pass perfusion
Male Wistar Han II rats weighing 265 ± 38 g were used in the study. The experiment was approved by the Institutional Review Board of Animal Care Committee of Institute of Experimental Biopharmaceutics, the Czech Academy of Sciences.
The modified perfusion method (Pang et al. 1986; Doherty and Pang 2000; Cong et al. 2001; Kuneš et al. 2005a ) was used in this initial study. A perfuser, composed of two reservoir units and two peristaltic pumps (S 31 Domet), was used for single-pass perfusion of rat small intestine. Krebs-Henseleit (K-H) solution was the perfusate (reservoir 1) flowing into the mesenterial bed. Phosphate buffer solution (pH 7.4) from reservoir 2 flows continuously into the lumen of small intestine. A thermostable plexiglass box (where the rat was placed) was used to maintain the temperature of the process at 37°C. K-H solution used as medium for mesenterial system perfusion was prepared before each experiment. It was prepared by mixing the distilled water, the basic solution and NaHCO 3 in proportion 4.2/1.05/1. The basic solution was mixed with NaCl, KCl, CaCl 2 , KH 2 PO 4 , MgSO 4 .7 H 2 O (all from Fluka). Final concentration of salts in 100 ml of K-H solution was: NaCl 706.8 mg, KCl 43.6 mg, CaCl 2 2.8 mg, KH 2 PO 4 16.5 mg, MgSO 4 .7 H 2 O 2.9 mg. Polyvinylpyrrolidone K25 (Fluka) has been added to K-H solution to colloidal balancing. This solution was gassed with 95%O 2 : 5%CO 2 and adjusted to pH 7.4 using 0.1 M HCl. Phosphate buffer solution (0.067 M) adjusted to pH 7.4 was the perfusate coming into the luminal part of small intestine.
Surgery was done in general anaesthesia (intraperitoneal dose of urethane, 1.5 g/kg, Sigma Aldrich). After laparotomy, superior mesenteric artery (inflow) and portal vein (outflow) were cannulated. The perfusion process using the perfusate from reservoir 1 (2.5 ml/min) was initiated immediately after the cannulation. Subsequently, duodenum was incised 3 cm below the stomach for administration of tablet core containing 5-ASA (100 mg mesalazine substance; prepared in the laboratory of PRO.MED.CS Praha a.s., Czech Republic). Before tablet core administration, the intestine had been subjected to a single flush by the blank phosphate buffer (40 ml; temperated to 37°C). After that, the cannula was fixed in the duodenal incision to introduce the perfusate under constant flow 0.4 ml/min from reservoir 2. For analysis, samples were withdrawn at 5, 10, 20, 30, 45, 60, 75 and 90 min from ileum and portal vein. The concentrations of 5-ASA and its metabolite N-ac-5-ASA in perfusate samples were detected by HPLC (Nobilis et al. 2006) .
Caco-2 cell experiments
Caco-2 cells (from the European Collection of Cell Culture (ECACC), Sigma-Aldrich, Czech Republic) were cultured in a standard manner (Bourdet and Thakker 2006; ) in plastic tissue culture flasks (TPP AG, Switzerland) in Dulbecco´s modified Eagle´s medium with high glucose (PAA Laboratories (BioTech, Czech Republic)) at 37°C in atmosphere of 5% CO 2 and 90% relative humidity. For 5-ASA transport studies, Caco-2 cells (passages 79-85) were seeded onto the Transwell inserts (TPP AG, Switzerland) at a density of 2.5 × 10 5 cells/cm 2 and grown to late confluence (22-24 days). Medium was changed three times a week and daily during the last 3-5 days (500 µl to the insert compartment -the apical side, and 650 µl to the well compartment -the basolateral side). Caco-2 cells were grown for at least 21 days to allow formation physiologically and morphologically (polarization, differentiation) well developed confluent cell monolayers prior to initiating drug transport studies (Hidalgo et al. 1989; Vachon and Beaulieu 1992; Walle and Walle 1998) .
Cell viability assay
Cell viability was determined by Trypan blue exclusion method (Lu et al. 2005; Smetanova et al. 2009 ). Caco-2 cells were seeded onto Petri dishes (area 9.2 cm 2 ) at a density of 2 × 10 5 cells/cm 2 and cultured for 24 h. 5-ASA (1000 µmol/l) or transport medium (as a control) was then added and incubated for 2 h. Then the cells were released from the dishes and incubated with 0.4% Trypan blue for 5 min and counted by using light microscopy.
Monolayer integrity assessment
Before the start of the experiment, the monolayer integrity was checked by 500 µmol/l phenol red permeability/ 1 h (Fleet and Wood 1999; Garcia-Casal et al. 2000; Smetanova et al. 2008) measured by spectrophotometry at 558 nm (Spekol 11). During transport studies, Caco-2 cell monolayer integrity was confirmed simultaneously by measuring 14 C-mannitol permeability (Artursson et al. 1996; Baird and Prosser 1998) .
14 C mannitol (0.5 µCi/ml; Moravek Radiochemical and Biochemicals (MGP Zlín, Czech Republic)) transport was examined in apical to basolateral direction for 2 h and samples were counted using liquid scintillation analyser (Beckman LS 5000TD).
Transport studies
Transport experiments with 5-ASA (Sigma-Aldrich, Czech Republic) were performed as previously described (Walle and Walle 1998; Stetinova et al. 2009; Smetanova et al. 2009 ). Briefly, the inserts were rinsed twice and equilibrated with prewarm Hanks´ balanced salt solution (HBSS; PAA Laboratories (BioTech, Czech Republic)) at 37°C for 30 min before the transport studies. The AP-BL (apical-to-basolateral) transport experiments were initiated by replacing the transport medium with the diluted 5-ASA (10, 100, 300, and 1000 µmol/l) in the transport medium on the apical side. The samples (500 µl) from the basolateral compartment were withdrawn at 30, 60, 90 and 120 min for HPLC analysis (determination of 5-ASA and metabolite N-ac-5-ASA). Similarly, for basolateral-to-apical (BL-AP) transport, the drug was added to the basolateral compartment and samples (300 µl) from the apical compartment withdrawn in the same time intervals. To determine paracellular component of the 5-ASA (300 µmol/l) transport, the HBSS Ca 2+ -free medium was used (for washes, 30 min preincubation and for the transport study).
Apparent permeability coefficient P app (cm/s) was calculated (Artursson and Karlsson 1991) :
where dQ/dt is the permeability rate, the amount of drug appearing in the receiver compartment in function of time (nmol/s), C 0 is the initial concentration in the donor chamber (nmol/ml), and A is the surface area of the monolayer (cm 2 ). Transport in both directions across monolayer enables to calculate (Ungell and Karlsson 2004) :
The flux rate (nmol/min/cm 2 ) of the 5-ASA was determined from the slope of the plot of the cumulatively transported amount versus time using linear regression analysis and the flux rates were plotted versus 5-ASA concentrations.
All used solutions and transport media were sterile filtered just before the experiments. All experiments were carried out under sink conditions so that the concentrations of the drug in the receiver compartment would not exceed 10% of applicated dose in the donor side.
HPLC analysis of 5-ASA and N-ac-5-ASA
The quantification of 5-ASA was performed by high performance liquid chromatography (HPLC) with gradient elution. A modified method of Nobilis et al. (2006) was used. Withdrawn samples in transport medium were analyzed for 5-ASA and N-ac-5-ASA. Chromatographic separation was performed on the analytical column LichroCART ® (250 × 4 mm) packed with Purospher RP-18e (5 μm) and precolumn LiChroCART® 4-4 with the same stationary phase (Merck, Darmstadt, Germany). The mobile phase A consisted of acetonitrile-UHQ water (8:2, v/v), the mobile phase B contained acetonitrile-0.01M Na 2 HPO 4 buffer (pH 3) in the ratio 15:85 (v/v). The flow-rate was 1 ml/min and elution of 5-ASA and N-ac-5-ASA was monitored at the fluorescence excitation wavelength of 300 nm and emission wavelength of 406 nm, the total run was 21 min for each sample. The quantitative determination was based upon the integration of fluorescence peak area.
Statistical analysis
All values are represented as mean ± standard deviation (SD). Statistical differences were determined using Kruskal-Wallis one way analysis of variance (ANOVA) with Scheffe´s post test. The differences were considered significant when p < 0.05. All treatments were carried out at least in triplicate (n = 3-4).
Results
Rat intestine in situ single-pass perfusion
After intraduodenal administration of tablets containing 5-ASA (100 mg), the amount of substance that reached the portal circulation during a 90-minute intestinal perfusion was 5.79 ± 0.24 %. The major metabolite of 5-ASA, i.e. N-ac-5-ASA, was detectable both in the intestinal perfusate (the luminal concentration of the metabolite reached 0.36% of parent drug 5-ASA), and in the portal circulation (0.07 ± 0.11%) (Fig. 1) .
Caco-2 cell experiments
Cell viability 5-aminosalicylic acid (5-ASA) in concentration of 1000 µmol/l did not influence Caco-2 cell viability in comparison with viability of Caco-2 cells incubated with transport medium (98.0 ± 0.7% vs. 98.6 ± 0.5%, not significant).
The monolayer integrity assessment
The P app value of phenol red/1 h was 0.64 ± 0.22 × 10 -6 cm/s and percent cumulative transport reached 0.18 ± 0.06%.
The P app of mannitol after 2 h was 1.93 ± 0.10 × 10 -6 cm/s (Fig. 2) and corresponded to the percent cumulative transport 1.46 ± 0.01%. There was no effect of 5-ASA in concentration of 300 µmol/l on the P app of 14 C mannitol (2.02 ± 0.01 × 10 -6 cm/s; Fig. 2 ).
Transport studies of total 5-ASA (sum of 5-ASA and intracellularly formed N-ac-5-ASA)
The cumulative transport of total 5-ASA
The cumulative transport of total 5-ASA (nmol; Fig. 3 ) was linear for up to 120 min over the concentration range examined for both directions (AP-BL and BL-AP) with the exception of the AP-BL transport in the dose of 1000 µmol/l where the transport was linear only up to 90 min. The BL-AP transport was higher than AP-BL in the concentrations of 300 and 1000 µmol/l and was almost the same in the concentrations of 10 and 100 µmol/l.
The permeability values (P app ) and efflux ratios of 5-ASA
The permeability values (P app ) of 5-ASA (Fig. 4) were higher in the BL-AP than in AP-BL direction in all used concentrations but the difference in the transport (AP-BL vs. BL-AP) was statistically significant only in the dose of 10 µmol/l (2.87 vs. 4.97 × 10 -6 cm/s). In the dose of 100, 300 and 1000 µmol/l the P app values were 1.20-0.66 × 10 -6 cm/s for AP-BL transport and 1.32-1.04 × 10 -6 cm/s in BL-AP direction, P app values decreased with the increased dose of 5-ASA. The P app values were significantly lower in the doses 100, 300 and 1000 µmol/l in comparison with the permeability of 5-ASA in the dose of 10 µmol/l both in AP-BL and BL-AP direction. The P app efflux ratio (Fig. 4) was almost the same for the doses 10, 300 and 1000 µmol/l (around 1.7) and was the lowest in the dose of 100 µmol/l (1.2).
The transport of the 14 C-mannitol (paracellular marker) and also the transport of 5-ASA (AP-BL; 300 µmol/l) was significantly enhanced (8.73-times and 46.8-times) by the use of the HBSS Ca 2+ -free transport medium in comparison with using transport medium with Ca 2+ . There was statistical difference between P app of 5-ASA and P app of 14 C-mannitol with the HBSS Ca 2+ -free transport medium (Fig. 2) .
The AP-BL and BL-AP flux rates
The AP-BL flux rate was lower than BL-AP flux rate; flux rates were not a simple linear function of 5-ASA concentrations but polynomic function of the concentrations, indicating saturability of the 5-ASA transport (Fig. 5) .
Transport studies of 5-ASA and intracellularly formed N-ac-5-ASA (separately)
The percent cumulative transport of the parent drug 5-ASA and its metabolite (N-ac-5-ASA), separately, in both directions (AP-BL and BL-AP) is shown in Fig. 6 (only 120 min interval).
The transport of 5-ASA
The transport of 5-ASA was higher in AP-BL vs. BL-AP direction in all used doses (10-1000 µmol/l; non significantly) and was the highest in the dose of 10 µmol/l (about 2%); with increasing the dose, the transport decreased to about 0.38 % in the highest used dose (1000 µmol/l).
The transport of N-ac-5-ASA
The transport of N-ac-5-ASA was higher in BL-AP direction vs. AP-BL direction (0.21-1.00% vs. 0.04-0.10%) with statistical significance in the dose of 10 and 300 µmol/l. The transport of metabolite in the BL-AP direction was the highest in the dose of 10 µmol/l (1.00%) and the lowest in the dose of 1000 µmol/l (0.21%).
There was statistical difference in the BL-AP transport of metabolite in the dose of 10 µmol/l vs. BL-AP transports of metabolite in other doses (100, 300 and 1000 µmol/l), but there was no statistical difference among BL-AP transports of metabolite in doses 100, 300 and 1000 µmol/l. There was no statistical difference among the AP-BL transports of metabolite in all used doses.
Comparison of the transport of 5-ASA and N-ac-5-ASA
The percent cumulative transport of 5-ASA (parent drug) was higher than transport of the metabolite N-ac-5-ASA in the AP-BL direction significantly in the doses 10-300 µmol/l and non significantly in the dose of 1000 µmol/l. Also in the BL-AP direction the cumulative transport of 5-ASA (parent drug) was higher than transport of the metabolite N-ac-5-ASA but significantly only in the dose of 10 µmol/l.
The appearance of N-ac-5-ASA in the donor and receiver compartment
The appearance of the intracellularly formed metabolite (Nac-5-ASA) in the donor and receiver compartment at the end of the experiment (120 min) after administration of 5-ASA in the concentration range (10-1000 µmol/l) to the donor compartment is shown in Table 1 .
The study of AP-BL transport of 5-ASA
In the study of AP-BL transport of 5-ASA (administration of 5-ASA to the apical (donor) compartment), higher concentrations of N-ac-5-ASA were seen in the donor compartment in comparison with the receiver (basolateral) compartment in the concentrations of 100-1000 µmol/l. In the dose of 10 µmol/l, the metabolite could have been determined neither in the donor nor in the receiver compartment.
The study of BL-AP transport of 5-ASA
In the study of BL-AP transport of 5-ASA (administration of 5-ASA to the basolateral (donor) compartment), higher concentrations of N-ac-5-ASA were also seen in the donor compartment (similarly as in the AP-BL transport) in comparison with the receiver (apical) compartment in the concentrations of 10-1000 µmol/l with one exception: in the dose of 300 µmol/l the concentration of the metabolite was higher in the receiver compartment.
Comparison of AP-BL vs. BL-AP transports of 5-ASA
Comparing the AP-BL and BL-AP transports (donor and receiver compartments, respectively), the concentrations of the metabolite were higher in the donor compartments in AP-BL vs. BL-AP directions (with exception of 10 µmol/l) and in the receiver compartments in the BL-AP direction in comparison with AP-BL transports.
Discussion
As regards the initial study (rat in situ model), the singlepass perfusion technique was utilized i) on the basis of our Table 1 . The appearance of intracellularly formed metabolite of 5-ASA (N-ac-5-ASA) in the donor and receiver compartment at the end of the AP-BL and BL-AP transport (120 min) after administration of 5-ASA (10-1000 µmol/l) to the donor compartment, respectively
0.00 ± 0.00 0.00 ± 0.01 0.13 ± 0.04 0.11 ± 0.08 100 1.44 ± 0.12 0.06 ± 0.00 0.81 ± 0.26 0.37 ± 0.02 300 1.88 ± 0.44 0.15 ± 0.01 0.18 ± 0.32 1.66 ± 0.11 1000 4.57 ± 0.31 0.58 ± 0.06 3.26 ± 0.43 2.14 ± 0.14 Data are expressed as mean ± SD. AP, apical; BL, basolateral; D, donor compartment; R, receiver compartment. experience of studying of various transport mechanisms in the rat intestine (Kuneš et al. 2005a (Kuneš et al. , 2005b and ii) on the basis of comparably similar literature data (Schurgers et al. 1986; Fagerholm et al. 1996) . This in situ method was primarily targeted for eventual confirmation of the biotransformation formation of 5-ASA metabolite (N-ac-5-ASA) selectively in the intestinal wall (excluding extraintestinal pharmacokinetic compartments, such as liver). The conversion of 5-ASA to N-acetyl metabolite was dose-dependent in the sense of parent drug concentration. In addition to this confirmation, the presence of N-ac-5-ASA in the perfusate that had passed through intestinal lumen was an interesting observation. This could indicate a possible exsorption of metabolite (depending on the concentration gradient) into the intestinal content. Based on these results subsequent studies of the metabolic activity on the Caco-2 monolayer model were carried out.
The first aim of the Caco-2 experiments was to estimate 5-ASA permeability and to categorize 5-ASA into one of the BCS classes on the basis of 5-ASA permeability and solubility. The values of 5-ASA P app s around 1 × 10 -6 cm/s (100-1000 µmol/l) indicate low-permeability drug. The solubility of 5-ASA was found to be 9.37 ± 0.02 mg/ml water at pH 7.4 (Tuğcu-Demiröz et al. 2004) . As for this solubility, 5-ASA is slightly soluble according to the semiquantitative range for solubility (Lipinski 2004) . According to low permeability and low solubility, 5-ASA should be classified as class IV of the BCS.
The second objective of the Caco-2 studies was to contribute to the determination of 5-ASA transepithelial transport mechanisms as in vitro experiments with transport of 5-ASA across Caco-2 monolayers have provided contradictory results so far. The cumulative transport of total 5-ASA (parent drug plus intracellularly formed Nacetyl metabolite) was linear with time in both directions and was concentration-and direction-dependent (BL-AP > AP-BL) in all concentrations (10-1000 µmol/l). Flux rates (J) indicated saturability of 5-ASA transport. The percent transport of total 5-ASA was the highest in the dose of 10 µmol/l (> 2% in both directions) with higher BL-AP than AP-BL transport (data not shown). In the other doses, the percent transport was about 0.5-1%. Also Zhou et al. (1999) showed the difference in the percent transport in the low vs. higher doses, 10-20% vs. 2-5%, respectively. To the contrary Xin et al. (2006) reported the percent concentration-independent transport of 5-ASA. Analysis of the percent transport of parent drug (5-ASA) and its metabolite (N-ac-5-ASA), separately, was done. The real transport of parent drug was higher in the AP-BL vs. BL-AP direction and was concentration-dependent (the highest in the dose of 10 µmol/l). It was in the contrary to higher BL-AP transport of total 5-ASA transport (as a sum of transport of parent drug plus metabolite). This was caused by considerably higher transport of N-ac-5-ASA in the BL-AP vs. AP-BL direction. This implies involvement of efflux transporter in the transport of metabolite from the cell to the apical chamber. As reported Yoshimura et al. (2009) , N-ac-5-ASA was discharged 5.3, 7.1, and 8.1-fold higher into the apical than into the basolateral site during 1, 2, and 4-hour incubations, respectively, after apical administration of 5-ASA (200 µmol/l) in Caco-2 cells. They also demonstrated that the apical efflux of N-ac-5-ASA is suppressed by inhibition of MRPs´ pumps located on apical membranes in Caco-2 cells. Also in our AP-BL transport study, N-ac-5-ASA was discharged in higher extent to the apical than to the basolateral compartment. This can imply saturation of the apical efflux or saturation of the metabolite formation.
Obtained efflux ratios (about 1.7) are, however, boundary for definition of active efflux involvement (Yazdanian et al. 2004; Yu and Zeng 2007) . Analogous value of efflux ratios of 5-ASA (100 µmol/l) were reported by Liang et al. (2000) who claimed that 5-ASA is not a substrate of efflux transporters. And also Xin et al. (2006) concluded that the intestinal secretion of 5-ASA observed in vivo is unlikely to be mediated by the efflux transporters P-gp or MRP2. However, in an agreement with Yoshimura et al. (2009) as mentioned above, our experiments suggested efflux of N-ac-5-ASA which could be the molecular mechanism of secretion of N-ac-5-ASA into the gut lumen. Clinical studies also indicated that this metabolite is secreted back from the enterocytes into the gut lumen (Goebell et al. 1993; Layer et al. 1995) .
Detail analysis of the percent transport of 5-ASA alone vs. N-ac-5-ASA that the transport of 5-ASA alone is lowering with increasing dose. In the dose of 10 and 100 µmol/l AP-BL percent transport was higher (vs. BL-AP), which might suggest a carrier-mediated transepithelial transport of the proper 5-ASA. König et al. (2011) demonstrated that intracellular accumulation of 5-ASA (20 µmol/l) is mediated by members of the OATP uptake transporter family. Domination of the passive transport in the higher doses is probable as the percent transport of the proper 5-ASA was almost the same in AP-BL and BL-AP direction. With regard to physicochemical properties of 5-ASA, more probable is the passive transepithelial transport of 5-ASA via paracellular pathway than via lipid membrane permeation (Zhou et al. 1999) . To confirm the paracellular component of the 5-ASA transport in the Caco-2 cells, we used the Ca 2+ -free transport medium for opening the tight junctions (Delie and Rubas 1997; Ungell and Karlsson 2004; McMillan et al. 2005) . When this Ca 2+ -free medium was used, the P app of 14 C mannitol (positive control for the paracellular pathway) was significantly increased and also the P app of 5-ASA (300 µmol/l) was significantly enhanced giving an evidence for the paracellular component involved in the 5-ASA transport.
Conclusion
The initial study (rat in situ model) showed the maximal rate of absorption of released 5-ASA during the first 60 min (under given experimental conditions). During perfusion, 5-ASA was transported across the intestinal wall. And simultaneously during this transport, 5-ASA was converted into the 5-ASA metabolite (N-ac-5-ASA).
The estimated low 5-ASA permeability and its low solubility enable to classify 5-ASA as class IV of the BCS. The transport of the total 5-ASA (parent drug plus intracellularly formed N-acetyl metabolite) was linear with time, concentration-and direction-dependent. Higher BL-AP (secretory) transport was mainly caused by higher transport of the metabolite (suggesting efflux transport of the metabolite). The transport of proper 5-ASA (parent drug) was saturable (transepithelial carrier-mediated) at low doses, dominated by passive, paracellular process in higher doses which was confirmed by increased 5-ASA transport using Ca 2+ -free transport medium. Thus, the 5-ASA transport is a coordination of several processes which go in the same or in the opposite direction depending on the concentration of 5-ASA and are further complicated by the intracellular metabolite production and by the metabolite transport.
